Deep Bleeder Acoustic Coagulation (DBAC)—part II: in vivo testing of a research prototype system

Table 3 Summary of in vivo test bed final exam therapy results

Test no.	Vessel type	Depth range	Depth of penetration	Dosing time (s)		Input acoustic power (W)	Focal intensity^a (W/cm²)	Lesion^b	Vessel occlusion^c
1	SFA	Shallow	4.7	30	30^e	225	472	Y	N
2	DFA	Deep	11.5	30		378	472	Y	N
3	SFA	Shallow	5.5	30	30	472	472	N	N
4	DFA	Shallow^d	7.8	30	30	472	472	Y	N
5^g	SFA	Shallow	5.2	60		257	472	Y	Partial
6	DFA	Deep	10.5	60		211	266	Y	N
7	SFA	Deep	9.2	60		195	266	Y	N
8	DFA	Deep	11.0	60		218	259	Y	N
9	DFA	Deep	10.8	18	60	225	266	Y	N
10^h	SFA	Shallow	5.2	60	30^f	257	472	Y	Y
11	DFA	Deep	10.7	60		223	266	Y	N
12	SFA	Shallow	5.6	60		249	486	Y	N

Exps 1–4: animal #101; Exps 5–8: animal #104; Exps 9–12: animal #103
^aIntensity values are spatial average and temporal average; all foci superposed with attenuation derated according to each respective beam path
^bStatus as regards the question: lesion around target region? (targeting assessment)
^cOcclusion determined by reduction or stop of flow as evidenced in post-therapy angiography
^dAlthough classified as shallow, location was at the border of the shallow-deep transition depth
^eProlonged dosing procedure: second dose delivered 27 min after first dose; also one Tx (25 % of aperture) hit array thermal shutoff limits during 30-s dosing
^fProlonged dosing procedure: second dose delivered 37 min after first dose
^gPartial occlusion animal (#104); skin burns noted with TMM divoting of the PVA
^hComplete occlusion animal (#103)

ISSN: 2050-5736